EUCTR2007-001049-16-GB进行中（未招募）1 期
A multi-centre, randomised, double blind, parallel group study to investigate the efficacy and tolerability of treatment (24 weeks double blind phase followed by open-label extension) with either vildagliptin ( Galvus) or placebo combined with metformin in achieving optimal glycaemic control in older patients with type 2 diabetes.
ovartis Pharmaceuticals UK Ltd0 个研究点目标入组 0 人开始时间: 2007年10月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or Female; (65 to 80 years old); patients with T2DM (diagnosed at least 3 months prior to visit 1) who have received metformin 500mg BD- 2000mg daily divided dose of metformin monotherapy for at least three months immediately prior to visit 1
- •body mass index of 20-45.0kg/m2 inclusive at visit 1
- •HbA1c from 6.6 - 8.0% inclusive at visit 1.
- •FPG,15mmol/L; written informed consent to participate in the study .
- •Male or non-fertile female
- •A non fertile female is defined as: post menopausal ( 12 months of natual (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40mIU/m); 6 weeks post bilateral oophorectomy with or without hysterctomy;or sterilised by tubal ligation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.A history of:
- •type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g., Cushing’s syndrome and acromegaly.
- •acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months.
- •2.Evidence of significant diabetic complications, e.g., symptomatic autonomic neuropathy, gastroparesis, as well as symptoms of worsening hyperglycaemia (i.e. polyuria, polydipsia, weight loss) in the absence of any intercurrent illness or other incidental circumstances potentially causing deterioration of glucose control.
- •3.Acute infections which may affect blood glucose control within 4 weeks prior to visit 1 and other concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
- •4.Any of the following within the past 6 months:
- •myocardial infarction (MI) (if the visit 1 ECG reveals patterns consistent with an old MI and the date of the event cannot be determined, then the patient can enter the study at the discretion of the investigator and the sponsor);
- •coronary artery bypass surgery or percutaneous coronary intervention;
- •unstable angina that is not pharmacologically controlled or stroke.
- •TIA in the last 6 months
- •5.Congestive heart failure (CHF) requiring pharmacological treatment other than loop diurectics, digoxin, ARB or any beta blocker.
- •6.Any of the following ECG abnormalities:
- •Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation
- •second degree AV block (Mobitz 1 and 2)
- •third degree AV block
- •prolonged QTc (> 500 msec)
- •8.Malignancy including leukaemia and lymphoma (not including basal cell skin cancer) within the last 5 years.
- •9.Liver disease such as cirrhosis or chronic active hepatitis.
- •10.Contraindications and warnings according to the UK label for metformin not listed in the other exclusion criteria.
- •If eGFR < 45ml/min as calculated by the MDRD formula then the patient should be excluded from the study
- •11.Chronic insulin treatment (> 4 weeks of treatment in the absence of an intercurrent illness) within the past 6 months.
- •12.Treatment with other oral antidiabetics within 3 months prior to visit 1.
- •13.Chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1.
- •14.Treatment with growth hormone or similar drugs.
- •15.Treatment with class Ia, Ib and Ic or III anti-arrhythmics.
- •16.Use of other investigational drugs at visit 1, or within 30 days or 5 half-lives of visit 1, whichever is longer, unless local health authority guidelines mandate a longer period.
- •17.Treatment with any drug with a known and frequent toxicity to a major organ system within the past 3 months (i.e., cytostatic drugs).
- •18.Any of the following significant laboratory abnormalities:
- •ALT, AST greater than 2 times the upper limit of the normal range at visit 1, confirmed by a repeat test within 3 working days.
- •Total bilirubin greater than 2 times the upper limit of the normal range at visit 1 and direct bilirubin greater than the upper limit of normal range at visit 1, confirmed by a repeated measure within 3 working days.
- •Hepatitis B or C positive (on blood test)
- •Clinically significant renal dysfunction as indicated by MDRD eGFR < 45ml/min.
- •Clinically significant TSH values outside of normal range at visit 1.
- •Clinically significant laboratory abnormalities, confirmed by
研究者
相似试验
招募中
不适用
HIPER-500KCT0002734Samsung Medical Center120
进行中（未招募）
不适用
The aim of this clinical study is to show efficacy and safety of cells in patients suffering from stress urinary incontinence and to show superiority of cells in female patients with stress urinary incontinence over placebo.Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patientsMedDRA version: 17.0Level: PTClassification code 10066218Term: Stress urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2010-021871-10-ATInnovacell Biotechnologie AG - Life Science Center Innsbruck372
进行中（未招募）
不适用
The aim of this clinical study is to show efficacy and safety of cells in patients suffering from stress urinary incontinence and to show superiority of cells in female patients with stress urinary incontinence over placebo.Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patientsMedDRA version: 14.1Level: PTClassification code 10066218Term: Stress urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2010-021871-10-BGInnovacell Biotechnologie AG - Life Science Center Innsbruck372
进行中（未招募）
不适用
The aim of this clinical study is to show efficacy and safety of cells in patients suffering from stress urinary incontinence and to show superiority of cells in female patients with stress urinary incontinence over placebo.Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patientsMedDRA version: 17.1Level: PTClassification code 10066218Term: Stress urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2010-021871-10-DEInnovacell Biotechnologie AG - Life Science Center Innsbruck372
进行中（未招募）
不适用
The aim of this clinical study is to show efficacy and safety of cells in patients suffering from stress urinary incontinence and to show superiority of cells in female patients with stress urinary incontinence over placebo.Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patientsMedDRA version: 18.0Level: PTClassification code 10066218Term: Stress urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2010-021871-10-CZInnovacell Biotechnologie AG - Life Science Center Innsbruck369